82278-73-7

Basic information

• Product Name: (S)-N-Boc-3-Bromophenylalanine
• Synonyms: BOC-L-3-BROMOPHE;BOC-L-3-BROMOPHENYLALANINE;BOC-3-BROMO-L-PHENYLALANINE;BOC-S-PHE(3-BR)-OH;BOC-PHE(3-BR)-OH;(S)-3-(3-BROMO-PHENYL)-2-TERT-BUTOXYCARBONYLAMINO-PROPIONIC ACID;(S)-N-BOC-3-BROMOPHENYLALANINE;(S)-N-ALPHA-T-BUTYLOXYCARBONYL-3-BROMO-PHENYLALANINE
• CAS NO: 82278-73-7
• Molecular Formula: C₁₄H₁₈BrNO₄
• Molecular Weight: 344.2
• EINECS: 1592732-453-0
• Product Categories: Amino Acids;Phenylalanine analogs and other aromatic alpha amino acids
• Mol File: 82278-73-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 106.1°C
• Boiling Point: 475.3 °C at 760 mmHg
• Flash Point: 241.2 °C
• Appearance: off-white powder
• Density: 1.5311 (rough estimate)
• Vapor Pressure: 7.71E-10mmHg at 25°C
• Refractive Index: 1.6500 (estimate)
• Storage Temp.: Store at 0°C
• PKA: 3.81±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: (S)-N-Boc-3-Bromophenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-Boc-3-Bromophenylalanine(82278-73-7)
• EPA Substance Registry System: (S)-N-Boc-3-Bromophenylalanine(82278-73-7)

Safety Data

• Safety Statements: S24/25:Avoid contact with skin and eyes.
• HazardClass: IRRITANT
• Hazardous Substances Data: 82278-73-7(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

Uses

N-Boc-3-bromo-L-phenylalanine is used as pharmaceutical intermediate.

InChI:InChI=1/C14H18BrNO4/c1-14(2,3)20-13(19)16-11(12(17)18)8-9-5-4-6-10(15)7-9/h4-7,11H,8H2,1-3H3,(H,16,19)(H,17,18)/p-1/t11-/m0/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 82311-69-1 (S)-2-amino-3-(3-bromophenyl)propanoic acid 
• 880347-42-2 2-amino-3-(3-bromo-phenyl)-N-((2R)-hydroxy-(1R)-methyl-2-phenyl-ethyl)-N-methyl-propionamide 
• 14473-91-7 3-bromocinnamic acid 

Downstream Products

• 82311-69-1 (S)-2-amino-3-(3-bromophenyl)propanoic acid 
• 1289646-78-1 (S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate 
• 1194550-59-8 (2S)-2-amino-3-(3-(methanesulfonyl)phenyl)propionic acid benzyl ester hydrochloride 
• 1194550-63-4 C₄₆H₄₀Cl₂N₂O₅S 
• 1194550-65-6 benzyl (S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-[3-(methylsulfonyl)phenyl]propanoate hydrochloride 
• 1194550-67-8 ((S)-benzyl 2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-methylsulfonyl)phenyl)propanoate 
• 1025967-78-5 (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid 
• 1289646-76-9 (S)-2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propanol 
• 608528-91-2 (S)-3-Biphenyl-3-yl-2-tert-butoxycarbonylamino-propionic acid 
• 1620084-10-7 (S)-tert-butyl (3-(3-bromophenyl)-1-((4-methoxyphenyl) (methyl)amino)-1-oxopropan-2-yl)carbamate 
• 1620084-05-0 (S)-tert-butyl (1-((4-methoxyphenyl)(methyl)amino)-1-oxo-3-(3-vinylphenyl)propan-2-yl)carbamate 

Relevant articles and documents

Preparation method of lifitegrast intermediate

The invention relates to a preparation method of a lifitegrast intermediate. The preparation method is implemented by the following route, has the advantages of short synthesis route, high yield and high safety, and is simple and convenient to operate and suitable for industrial production. According to the preparation method, a compound II reacts with metal zinc in an organic solvent to generatean organic zinc reagent, a compound I carries out a coupling reaction with the organic zinc reagent, a palladium reagent and a phosphorus ligand to obtain a compound III, and Boc protecting groups ofthe compound III are removed to obtain a compound IV, wherein R1 and R2 groups are respectively and independently selected from methyl, ethyl, vinyl, n-propyl, isopropyl, propenyl, propynyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, butenyl, cyclobutyl, n-pentyl, iso-pentyl, cyclopentyl, n-hexyl, cyclohexyl, phenyl and benzyl.

LFA-1 INHIBITOR AND POLYMORPH THEREOF

Methods of preparation and purification of a compound, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA -1 mediated diseases are also disclosed.

MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE

The invention provides compounds inhibitory to the Hepatitis C viral protease, compositions and combinations including the compounds, methods of treatment of conditions wherein inhibition of the Hepatitis C viral protease is medically indicated, and metho